Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results Of APD791 For The Treatment Of Arterial Thrombosis

 10.07.2008 05:13   medicalnewstoday.com

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis and other related conditions.

World Cardiology